ライフサイエンスコーパス: hypertrophic obstructive cardiomyopathy

1 and hemodynamic improvement in patients with hypertrophic obstructive cardiomyopathy.

2 amic parameters in patients with symptomatic hypertrophic obstructive cardiomyopathy.

3 of patients with refractory symptoms due to hypertrophic obstructive cardiomyopathy.

4 minant of clinical symptoms in patients with hypertrophic obstructive cardiomyopathy.

5 r pacing in patients with severe symptoms of hypertrophic obstructive cardiomyopathy.

6 ptoms and decrease gradient in patients with hypertrophic obstructive cardiomyopathy.

7 ablation for the treatment of patients with hypertrophic obstructive cardiomyopathy.

8 d for all patients with severely symptomatic hypertrophic obstructive cardiomyopathy.

9 n the symptomatic treatment of patients with hypertrophic obstructive cardiomyopathy.

10 rgoing alcohol septal ablation treatment for hypertrophic obstructive cardiomyopathy, a human model o

11 ies in patients with refractory, symptomatic hypertrophic obstructive cardiomyopathy and significant

12 ck-sinus syndrome, neurocardiogenic syncope, hypertrophic obstructive cardiomyopathy, and cardiac res

13 nonsurgical septal reduction for symptomatic hypertrophic obstructive cardiomyopathy at our instituti

14 ow tract obstruction from aortic stenosis or hypertrophic obstructive cardiomyopathy but can also sug

15 emaker in patients with severely symptomatic hypertrophic obstructive cardiomyopathy can relieve symp

16 Because hypertrophic obstructive cardiomyopathy, dilated cardiom

17 to result in improved clinical outcomes for hypertrophic obstructive cardiomyopathy, dilated cardiom

18 Patients with hypertrophic obstructive cardiomyopathy have left ventri

19 tflow tract (LVOT) velocity in patients with hypertrophic obstructive cardiomyopathy (HCM).

20 ow tract (LVOT) obstruction in patients with hypertrophic obstructive cardiomyopathy (HOCM) both acut

21 Hypertrophic obstructive cardiomyopathy (HOCM) is charac

22 ve (MV) surgery are unknown in patients with hypertrophic obstructive cardiomyopathy (HOCM) undergoin

23 uated in symptomatic pediatric patients with hypertrophic obstructive cardiomyopathy (HOCM) unrespons

24 evaluate follow-up results in patients with hypertrophic obstructive cardiomyopathy (HOCM) who under

25 sitive/phenotype negative), 10 patients with hypertrophic obstructive cardiomyopathy (HOCM), 10 patie

26 myocardial infarction (MI) in patients with hypertrophic obstructive cardiomyopathy (HOCM).

27 apy (surgical myectomy) for the treatment of hypertrophic obstructive cardiomyopathy (HOCM).

28 novel therapeutic strategy for patients with hypertrophic obstructive cardiomyopathy (HOCM).

29 dient and improves symptoms in patients with hypertrophic obstructive cardiomyopathy (HOCM).

30 surgical septal reduction therapy (NSRT) for hypertrophic obstructive cardiomyopathy (HOCM).

31 my with dual-chamber pacing in patients with hypertrophic obstructive cardiomyopathy (HOCM).

32 sessing response to therapy in patients with hypertrophic obstructive cardiomyopathy (HOCM).

33 a new promising treatment for patients with hypertrophic obstructive cardiomyopathy (HOCM).

34 on is frequently responsible for symptoms in hypertrophic obstructive cardiomyopathy (HOCM).

35 ) with septal myectomy (SM) for treatment of hypertrophic obstructive cardiomyopathy (HOCM).

36 tion and exercise tolerance in patients with hypertrophic obstructive cardiomyopathy (HOCM).

37 affirm the efficacy of surgical treatment of hypertrophic obstructive cardiomyopathy in patients who

38 Hypertrophic obstructive cardiomyopathy is an inherited

39 Hypertrophic obstructive cardiomyopathy patients (N = 87

40 Of 173 consecutive hypertrophic obstructive cardiomyopathy patients who und

41 s used for treatment of medically refractory hypertrophic obstructive cardiomyopathy patients with se

42 d a reduction in dynamic obstruction in most hypertrophic obstructive cardiomyopathy patients.

43 A subgroup of patients with hypertrophic obstructive cardiomyopathy remain severely

44 wenty-one patients with severely symptomatic hypertrophic obstructive cardiomyopathy were entered int

45 ent relief of symptoms in most patients with hypertrophic obstructive cardiomyopathy who are severely

46 yzed for 65 patients 20 to 70 years old with hypertrophic obstructive cardiomyopathy who had surgical

47 dictive of clinical outcome in patients with hypertrophic obstructive cardiomyopathy who undergo sept

48 Fifty patients with hypertrophic obstructive cardiomyopathy who underwent no

49 n polymerase chain reaction in patients with hypertrophic obstructive cardiomyopathy who were undergo

50 ective therapy for symptomatic patients with hypertrophic obstructive cardiomyopathy with persistence